Abstract:Chronic obstructive pulmonary disease (COPD) is a major cause of death worldwide. Acute exacerbations COPD (AECOPD), caused by infectious and non-infectious agents, contribute to an increase in mortality. The diagnostic procedure of AECOPD is mainly based on clinical features. The aim of this pilot study was to identify whether volatile organic compounds (VOCs) in breath could be used to discriminate for acute exacerbated COPD. Three patient groups were included in this controlled study: AECOPD patients (n = 14, age mean ± SD: 71.4 ± 7.46), stable COPD patients (n = 16, age mean ± SD: 66.9 ± 9.05) and healthy volunteers (n = 24, age mean ± SD: 28 ± 6.08). Breath samples were collected by optimizing a sampling strategy developed by us. These samples were then analyzed using a thermal desorption-gas chromatography-time of flight-mass spectrometer (TD-GC-ToF-MS). A total of 105 VOCs were identified in the breath samples. Relevant substances were subsequently selected by overall occurrence rate, the frequency of positive alveolar gradient (AG) (i.e. the difference in exhaled and inhaled VOCs concentration), exclusion of 'smoking related' VOCs and significant differences in AGs between the three groups. These steps dramatically reduced the number of relevant analytes and resulted in 12 key VOCs having discriminative values. The performance of patients' classification described by the Receiver Operating Characteristic (ROC) curve using all 12 substances delineates an area under the curve (AUC) of 0.97. A further reduction to four VOCs (AGs only different between AECOPD and COPD) delineates an AUC of 0.92. These results indicate that breath analysis with TD-GC-ToF-MS holds promise for an accurate and easy to perform differential diagnosis between AECOPD and COPD. In this regard, ketones were observed at the highest levels in exhaled breath of AECOPD, some of which are also related to potential bacterial pathogens. Using a set of VOCs that can discriminate for AECOPD, the calculated AUCs in ROC curve analysis show far superior results in comparison to serum AECOPD biomarkers, such as C-reactive protein. The identified VOCs should be further investigated in translational studies addressing their potential for developing highly specific nanosensors for breath gas analysis which would give clinicians a tool for non-invasive diagnosis of AECOPD at the point of care.

Discriminative potential of exhaled breath condensate biomarkers with respect to chronic obstructive pulmonary disease

The Implication of Biomarkers in Exhaled Breath Condensate of Chronic Obstructive Pulmonary Disease

Application of exhaled breath condensate in early diagnosis of lung cancer

Determination of Biomarkers in Exhaled Breath Condensation of Acute Exacerbation of Chronic Obstructive Pulmonary Disease and Its Clinical Implications

Analysis of volatile organic compounds in the breath of patients with stable or acute exacerbation of chronic obstructive pulmonary disease

Clinical Application of Exhaled Breath Condensate in Diagnosis of Diseases

Stable COPD Picture through Exhaled Breath Condensate, Questionnaires and Tests. A Proof of Concept Study

The Role of Exhaled Breath Condensate in Chronic Inflammatory and Neoplastic Diseases of the Respiratory Tract

A dual center study to compare breath volatile organic compounds from smokers and non-smokers with and without COPD

Biomarkers obtained by non-invasive methods in patients with COPD: where do we stand, what do we expect?

The Non-Invasive Detection of Pulmonary Exacerbations in Disorders of Mucociliary Clearance with Breath Analysis: A Systematic Review

Identification of Sputum Biomarkers Predictive of Pulmonary Exacerbations in COPD.

P-117 ASSESSING EXHALED BREATH CONDENSATE AS MINIMALLY INVASIVE MATRIX FOR LUNG-RELATED BIOMARKER ANALYSES

Exhaled Breath Condensate—A Non-Invasive Approach for Diagnostic Methods in Asthma

Biomarkers in exhaled breath condensate as fingerprints of asthma, chronic obstructive pulmonary disease and asthma–chronic obstructive pulmonary disease overlap: a critical review

Oxidative Stress and Inflammatory Mediators in Exhaled Breath Condensate of Patients with Pulmonary Tuberculosis. A Pilot Study with a Biomarker Perspective

The role of volatile organic compounds for assessing characteristics and severity of non-cystic fibrosis bronchiectasis: an observational study

Metabolomics of COPD Pulmonary Rehabilitation Outcomes via Exhaled Breath Condensate

Exhaled breath condensate levels of 8-isoprostane, growth related oncogene alpha and monocyte chemoattractant protein-1 in patients with chronic obstructive pulmonary disease

Exhaled breath condensate (EBC) in respiratory diseases: Recent advances, and future perspectives in the age of Omic sciences

Machine learning methods on exhaled volatile organic compounds for distinguishing COPD patients from healthy controls